Literature DB >> 15973152

B7-homolog 1 expression by human glioma: a new mechanism of immune evasion.

Rick Wilmotte1, Karim Burkhardt, Vincent Kindler, Marie-Claude Belkouch, Géraldine Dussex, Nicolas de Tribolet, Paul R Walker, Pierre-Yves Dietrich.   

Abstract

Immunosuppressive soluble factors such as transforming growth factor beta and cell surface molecules such as FasL may contribute to the immune evasion of malignant glioma. B7 homolog 1 is a member of the B7 family of costimulatory molecules implicated in the negative regulation of T cell immune responses. Here, we show that human glioma cell lines express B7 homolog 1 protein that reduces interferon-gamma production by activated T cells. The expression of B7 homolog 1 in vivo was demonstrated in a large series of human glioma samples, with a significant correlation between the level of B7 homolog 1 expression and the tumor grade. Overall, our data suggest that B7 homolog 1 may be involved in the immune evasion of glioma and encourage the blockade of this pathway in future immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15973152     DOI: 10.1097/00001756-200507130-00010

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  50 in total

Review 1.  Targeted Therapies for the Treatment of Glioblastoma in Adults.

Authors:  Ding Fang Chuang; Xuling Lin
Journal:  Curr Oncol Rep       Date:  2019-05-17       Impact factor: 5.075

2.  Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion.

Authors:  Seunggu J Han; Brian J Ahn; James S Waldron; Isaac Yang; Shanna Fang; Courtney A Crane; Russell O Pieper; Andrew T Parsa
Journal:  Neuroreport       Date:  2009-12-09       Impact factor: 1.837

3.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

4.  Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.

Authors:  Szu-Ting Chou; Rameshwar Patil; Anna Galstyan; Alexander V Ljubimov; Julia Y Ljubimova; Pallavi R Gangalum; Webster K Cavenee; Frank B Furnari; Vladimir A Ljubimov; Alexandra Chesnokova; Andrei A Kramerov; Hui Ding; Vida Falahatian; Leila Mashouf; Irving Fox; Keith L Black; Eggehard Holler
Journal:  J Control Release       Date:  2016-11-05       Impact factor: 9.776

5.  Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

Authors:  Kyu Sang Lee; Kyoungyul Lee; Sumi Yun; Seyoung Moon; Yujun Park; Jung Ho Han; Chae-Yong Kim; Hye Seung Lee; Gheeyoung Choe
Journal:  J Neurooncol       Date:  2017-11-16       Impact factor: 4.130

Review 6.  Microenvironmental clues for glioma immunotherapy.

Authors:  Michael Platten; Katharina Ochs; Dieter Lemke; Christiane Opitz; Wolfgang Wick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

7.  Clinical retrospective study on the expression of the PD-L1 molecule in sporadic colorectal cancer and its correlation with K-ras gene mutations in Chinese patients.

Authors:  Jiasheng Xu; Wenpeng Zhao; Kaili Liao; Luxia Tu; Xiaozhen Jiang; Hua Dai; Yanqing Yu; Qiuying Xiong; Zhenfang Xiong
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 8.  Glioblastoma stem cells and stem cell-targeting immunotherapies.

Authors:  Rogelio Esparza; Tej D Azad; Abdullah H Feroze; Siddhartha S Mitra; Samuel H Cheshier
Journal:  J Neurooncol       Date:  2015-02-15       Impact factor: 4.130

9.  Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.

Authors:  Katherine Riccione; Carter M Suryadevara; David Snyder; Xiuyu Cui; John H Sampson; Luis Sanchez-Perez
Journal:  J Vis Exp       Date:  2015-02-16       Impact factor: 1.355

Review 10.  Overview of cellular immunotherapy for patients with glioblastoma.

Authors:  Elodie Vauleon; Tony Avril; Brigitte Collet; Jean Mosser; Véronique Quillien
Journal:  Clin Dev Immunol       Date:  2010-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.